Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors

A. Pariente, A. Fourrier-Réglat, F. Bazin, T. Ducruet, J. F. Dartigues, A. Dragomir, S. Perreault, N. Moore, Yola Moride

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To determine the effect of treatment gaps on the risk of institutionalization or death among community-dwelling elderly patients treated with cholinesterase inhibitors (ChIs). Methods: A survival analysis was conducted among a cohort of community-dwelling elderly patients (age 66+) newly treated with ChIs identified in the Quebec drug claims databases (Régie de l'Assurance Maladie du Québec [RAMQ]) between January 1, 2000, and December 31, 2007. Treatment nonpersistence during the year following ChI initiation was defined as treatment discontinuation or gaps of at least 6 weeks. To account for reverse causality, Cox proportional hazard modeling was conducted only among patients who did not discontinue treatment, in order to assess the association between treatment nonpersistence and institutionalization or death. Results: Among the 24,394 elderly ChI users, 4,108 (16.8%) experienced a treatment gap during the year following ChI treatment initiation while 596 (2.4%) discontinued their treatment within the first 3 months (early stoppers) and 4,038 (16.6%) after 3 months of treatment (late stoppers). Of all treated patients, 4,409 (18.1%) were institutionalized or died during follow-up. In patients who did not stop their treatment, the risk of institutionalization or death appeared lower in patients who experienced a treatment gap (hazard ratio 0.91; 95% confidence interval 0.86-0.96). Conclusions: Our results suggest that, contrary to what was previously reported in clinical trials, treatment gaps do not compromise the outcome of patients treated with ChIs in a real-life setting.

Original languageEnglish (US)
Pages (from-to)957-963
Number of pages7
JournalNeurology
Volume78
Issue number13
DOIs
StatePublished - Mar 27 2012
Externally publishedYes

Fingerprint

Cholinesterase Inhibitors
Dementia
Institutionalization
Therapeutics
Independent Living
Pharmaceutical Databases
Quebec
Survival Analysis
Causality
Clinical Trials
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Pariente, A., Fourrier-Réglat, A., Bazin, F., Ducruet, T., Dartigues, J. F., Dragomir, A., ... Moride, Y. (2012). Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology, 78(13), 957-963. https://doi.org/10.1212/WNL.0b013e31824d5773
Pariente, A. ; Fourrier-Réglat, A. ; Bazin, F. ; Ducruet, T. ; Dartigues, J. F. ; Dragomir, A. ; Perreault, S. ; Moore, N. ; Moride, Yola. / Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. In: Neurology. 2012 ; Vol. 78, No. 13. pp. 957-963.
@article{34ff04dc754249928f931d1303361c6f,
title = "Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors",
abstract = "Objective: To determine the effect of treatment gaps on the risk of institutionalization or death among community-dwelling elderly patients treated with cholinesterase inhibitors (ChIs). Methods: A survival analysis was conducted among a cohort of community-dwelling elderly patients (age 66+) newly treated with ChIs identified in the Quebec drug claims databases (R{\'e}gie de l'Assurance Maladie du Qu{\'e}bec [RAMQ]) between January 1, 2000, and December 31, 2007. Treatment nonpersistence during the year following ChI initiation was defined as treatment discontinuation or gaps of at least 6 weeks. To account for reverse causality, Cox proportional hazard modeling was conducted only among patients who did not discontinue treatment, in order to assess the association between treatment nonpersistence and institutionalization or death. Results: Among the 24,394 elderly ChI users, 4,108 (16.8{\%}) experienced a treatment gap during the year following ChI treatment initiation while 596 (2.4{\%}) discontinued their treatment within the first 3 months (early stoppers) and 4,038 (16.6{\%}) after 3 months of treatment (late stoppers). Of all treated patients, 4,409 (18.1{\%}) were institutionalized or died during follow-up. In patients who did not stop their treatment, the risk of institutionalization or death appeared lower in patients who experienced a treatment gap (hazard ratio 0.91; 95{\%} confidence interval 0.86-0.96). Conclusions: Our results suggest that, contrary to what was previously reported in clinical trials, treatment gaps do not compromise the outcome of patients treated with ChIs in a real-life setting.",
author = "A. Pariente and A. Fourrier-R{\'e}glat and F. Bazin and T. Ducruet and Dartigues, {J. F.} and A. Dragomir and S. Perreault and N. Moore and Yola Moride",
year = "2012",
month = "3",
day = "27",
doi = "10.1212/WNL.0b013e31824d5773",
language = "English (US)",
volume = "78",
pages = "957--963",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

Pariente, A, Fourrier-Réglat, A, Bazin, F, Ducruet, T, Dartigues, JF, Dragomir, A, Perreault, S, Moore, N & Moride, Y 2012, 'Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors', Neurology, vol. 78, no. 13, pp. 957-963. https://doi.org/10.1212/WNL.0b013e31824d5773

Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. / Pariente, A.; Fourrier-Réglat, A.; Bazin, F.; Ducruet, T.; Dartigues, J. F.; Dragomir, A.; Perreault, S.; Moore, N.; Moride, Yola.

In: Neurology, Vol. 78, No. 13, 27.03.2012, p. 957-963.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors

AU - Pariente, A.

AU - Fourrier-Réglat, A.

AU - Bazin, F.

AU - Ducruet, T.

AU - Dartigues, J. F.

AU - Dragomir, A.

AU - Perreault, S.

AU - Moore, N.

AU - Moride, Yola

PY - 2012/3/27

Y1 - 2012/3/27

N2 - Objective: To determine the effect of treatment gaps on the risk of institutionalization or death among community-dwelling elderly patients treated with cholinesterase inhibitors (ChIs). Methods: A survival analysis was conducted among a cohort of community-dwelling elderly patients (age 66+) newly treated with ChIs identified in the Quebec drug claims databases (Régie de l'Assurance Maladie du Québec [RAMQ]) between January 1, 2000, and December 31, 2007. Treatment nonpersistence during the year following ChI initiation was defined as treatment discontinuation or gaps of at least 6 weeks. To account for reverse causality, Cox proportional hazard modeling was conducted only among patients who did not discontinue treatment, in order to assess the association between treatment nonpersistence and institutionalization or death. Results: Among the 24,394 elderly ChI users, 4,108 (16.8%) experienced a treatment gap during the year following ChI treatment initiation while 596 (2.4%) discontinued their treatment within the first 3 months (early stoppers) and 4,038 (16.6%) after 3 months of treatment (late stoppers). Of all treated patients, 4,409 (18.1%) were institutionalized or died during follow-up. In patients who did not stop their treatment, the risk of institutionalization or death appeared lower in patients who experienced a treatment gap (hazard ratio 0.91; 95% confidence interval 0.86-0.96). Conclusions: Our results suggest that, contrary to what was previously reported in clinical trials, treatment gaps do not compromise the outcome of patients treated with ChIs in a real-life setting.

AB - Objective: To determine the effect of treatment gaps on the risk of institutionalization or death among community-dwelling elderly patients treated with cholinesterase inhibitors (ChIs). Methods: A survival analysis was conducted among a cohort of community-dwelling elderly patients (age 66+) newly treated with ChIs identified in the Quebec drug claims databases (Régie de l'Assurance Maladie du Québec [RAMQ]) between January 1, 2000, and December 31, 2007. Treatment nonpersistence during the year following ChI initiation was defined as treatment discontinuation or gaps of at least 6 weeks. To account for reverse causality, Cox proportional hazard modeling was conducted only among patients who did not discontinue treatment, in order to assess the association between treatment nonpersistence and institutionalization or death. Results: Among the 24,394 elderly ChI users, 4,108 (16.8%) experienced a treatment gap during the year following ChI treatment initiation while 596 (2.4%) discontinued their treatment within the first 3 months (early stoppers) and 4,038 (16.6%) after 3 months of treatment (late stoppers). Of all treated patients, 4,409 (18.1%) were institutionalized or died during follow-up. In patients who did not stop their treatment, the risk of institutionalization or death appeared lower in patients who experienced a treatment gap (hazard ratio 0.91; 95% confidence interval 0.86-0.96). Conclusions: Our results suggest that, contrary to what was previously reported in clinical trials, treatment gaps do not compromise the outcome of patients treated with ChIs in a real-life setting.

UR - http://www.scopus.com/inward/record.url?scp=84860789019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860789019&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31824d5773

DO - 10.1212/WNL.0b013e31824d5773

M3 - Article

C2 - 22422894

AN - SCOPUS:84860789019

VL - 78

SP - 957

EP - 963

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 13

ER -

Pariente A, Fourrier-Réglat A, Bazin F, Ducruet T, Dartigues JF, Dragomir A et al. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012 Mar 27;78(13):957-963. https://doi.org/10.1212/WNL.0b013e31824d5773